ArticleFrontiers in microbiology2020
Genomic and Phenotypic Analysis of an ESBL-Producing
Article in Frontiers in microbiology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 11 citations in OpenAlex.
- Longitudinal Study on Extended-Spectrum Beta-Lactamase-Microorganisms · 2022Article
- Multidrug-Resistant High-RiskAntibiotics (Basel, Switzerland) · 2022Article
- Highly Virulent and Multidrug-ResistantAntibiotics (Basel, Switzerland) · 2022Article
- Extensively Drug-Resistant Klebsiella pneumoniae Counteracts Fitness and Virulence Costs That Accompanied Ceftazidime-Avibactam Resistance Acquisition.Microbiology spectrum · 2022Article
- Removal of Extended-Spectrum Beta-Lactamase-ProducingInternational journal of environmental research and public health · 2022Article
- HypervirulentInternational journal of molecular sciences · 2021Article
- A Klebsiella pneumoniae ST307 outbreak clone from Germany demonstrates features of extensive drug resistance, hypermucoviscosity, and enhanced iron acquisition.Genome medicine · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIn addition to the broad dissemination of pathogenic extended-spectrum beta-lactamase (ESBL)-producing
objectivesWe analyzed ESBL-producing and non-ESBL-producing
methodsWe investigated ESBL-producing RESULTS AND
conclusionWe found ESBL-producing
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.